GRITTI, GIUSEPPE
 Distribuzione geografica
Continente #
AS - Asia 2.533
NA - Nord America 1.954
EU - Europa 872
SA - Sud America 401
AF - Africa 72
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 5.834
Nazione #
US - Stati Uniti d'America 1.831
SG - Singapore 750
VN - Vietnam 694
CN - Cina 439
BR - Brasile 308
HK - Hong Kong 279
IT - Italia 256
RU - Federazione Russa 151
CA - Canada 76
DE - Germania 74
SE - Svezia 69
KR - Corea 67
IN - India 64
IE - Irlanda 63
FR - Francia 54
GB - Regno Unito 54
BD - Bangladesh 49
AR - Argentina 33
ID - Indonesia 33
ZA - Sudafrica 30
UA - Ucraina 29
MX - Messico 27
TR - Turchia 26
ES - Italia 22
PK - Pakistan 17
FI - Finlandia 16
JP - Giappone 16
PH - Filippine 16
PL - Polonia 16
NL - Olanda 14
SA - Arabia Saudita 14
EC - Ecuador 13
IQ - Iraq 11
UZ - Uzbekistan 11
VE - Venezuela 11
MA - Marocco 10
AT - Austria 9
CL - Cile 8
CO - Colombia 8
KE - Kenya 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 6
BE - Belgio 6
CH - Svizzera 6
DZ - Algeria 6
LB - Libano 6
PT - Portogallo 6
AZ - Azerbaigian 5
JO - Giordania 5
KZ - Kazakistan 5
MY - Malesia 5
NP - Nepal 5
PA - Panama 5
PY - Paraguay 5
EG - Egitto 4
BO - Bolivia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
JM - Giamaica 3
LT - Lituania 3
PE - Perù 3
TN - Tunisia 3
AL - Albania 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
IL - Israele 2
LY - Libia 2
MD - Moldavia 2
NO - Norvegia 2
RO - Romania 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
MK - Macedonia 1
MU - Mauritius 1
NI - Nicaragua 1
OM - Oman 1
RE - Reunion 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 5.833
Città #
Singapore 416
Hong Kong 270
San Jose 269
Ashburn 234
Ho Chi Minh City 213
Hanoi 181
Hefei 136
Ann Arbor 97
New York 73
Seoul 65
Los Angeles 64
The Dalles 64
Milan 63
Chandler 62
Dublin 60
Chicago 54
Beijing 51
Santa Clara 45
Toronto 45
Frankfurt am Main 44
Woodbridge 42
Fairfield 38
São Paulo 37
Lauterbourg 35
Dallas 34
Wilmington 28
Houston 27
Jakarta 25
Buffalo 24
Da Nang 24
Council Bluffs 22
Haiphong 22
Moscow 20
Seattle 20
Johannesburg 18
Princeton 18
Denver 17
Jacksonville 16
Lissone 16
Quận Bình Thạnh 16
Brooklyn 15
Tokyo 15
Warsaw 15
Absecon 14
Ha Long 14
London 14
Cambridge 13
Shanghai 13
Hải Dương 12
Poplar 12
Chennai 11
Montreal 11
Tashkent 11
Biên Hòa 10
Orem 10
Stockholm 10
Thái Nguyên 10
Tianjin 10
Vũng Tàu 10
Atlanta 9
Bắc Giang 9
Dearborn 9
Jeddah 9
Mexico City 9
Genoa 8
Lawrence 8
Manchester 8
Mumbai 8
Boston 7
Brescia 7
Bắc Ninh 7
Dhaka 7
Florence 7
Miami 7
Montevideo 7
Munich 7
Nairobi 7
New Delhi 7
Ninh Bình 7
Nuremberg 7
Phoenix 7
Phủ Lý 7
Rio de Janeiro 7
Rome 7
Altamura 6
Barnet 6
Belo Horizonte 6
Bergamo 6
Brasília 6
Brussels 6
Can Tho 6
Curitiba 6
Guangzhou 6
Istanbul 6
Quận Sáu 6
San Diego 6
San Francisco 6
Vienna 6
Andover 5
Arezzo 5
Totale 3.518
Nome #
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 430
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study 320
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 272
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 249
Development of new therapeutic strategies in mature T-cell non-Hodgkin lymphomas 236
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia 229
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 228
Skip pattern approach toward the early access of innovative anticancer drugs 228
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial 227
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 180
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 175
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 158
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma 157
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 149
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma 144
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy 138
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up 130
Genetic and phenotypic attributes of splenic marginal zone lymphoma 128
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study 127
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia 125
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study 122
Chimeric antigen receptor T cells for gamma–delta T cell malignancies 122
Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659 117
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 116
Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab 115
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 113
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma 110
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 109
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL 105
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C 102
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis 100
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface 99
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma 86
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma 86
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 82
SAKK38/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model 73
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma 73
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure 71
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models 68
Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies 63
Totale 5.962
Categoria #
all - tutte 16.648
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.648


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 0 5 14
2021/2022144 9 9 11 11 15 11 6 17 3 11 15 26
2022/2023209 25 53 25 15 12 34 8 10 20 1 3 3
2023/2024167 7 2 6 13 20 34 34 6 14 6 4 21
2024/20251.012 15 42 26 19 34 121 70 52 117 189 125 202
2025/20264.040 665 445 278 511 448 190 563 156 310 340 134 0
Totale 5.962